Complement activation defects in pediatric oncology patients: hidden factors contributing to the increased risk of infection.

Complement activation defects in pediatric oncology patients: hidden factors contributing to the increased risk of infection. - Complement-study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON37745

Enrollment

160

Registered

2012-07-31

Start date

2012-09-04

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complement activation defects risk of infection

Interventions

None listed

Eligibility

Age

2 Years to 17 Years

Inclusion criteria

Inclusion criteria: All (newly) diagnosed pediatric oncology patients, irrespective of the tumor type or its treatment Admittance for chemotherapy course as treatment of the malignancy Admittance for treatment of a suspected or proven infection

Exclusion criteria

Exclusion criteria: Post-hoc exclusion may be applicable for the patients who are septic at the time of inclusion, because complement consumption may occur as a consequence of the overwhelming infection. On the other hand, complement defects may increase the risk of infections.

Design outcomes

Primary

Measure	Time frame
Complement activation defects (objective 1 & 2).	—

Secondary

Measure	Time frame
Determination of the prevalence of the complement defects in complement activation in pediatric oncology patients in relation to the type of malignancy (leukemia, lymphoma, solid tumor), oncological treatment (chemotherapy, radiotherapy, surgery, or combinations hereof), potential loss or sequestration of complement factors [severity and duration of febrile neutropenia, proven infections, gastrointestinal complication, tumor lysis = estimated tumor mass] and potential lack of synthesis of complement factors [liver function, BM suppression].	—

Measure

Time frame

Determination of the prevalence of the complement defects in complement activation in pediatric oncology patients in relation to the type of malignancy (leukemia, lymphoma, solid tumor), oncological treatment (chemotherapy, radiotherapy, surgery, or combinations hereof), potential loss or sequestration of complement factors [severity and duration of febrile neutropenia, proven infections, gastrointestinal complication, tumor lysis = estimated tumor mass] and potential lack of synthesis of complement factors [liver function, BM suppression].

—

Countries

Netherlands

Outcome results